LGDN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Royalty Revenue GrowthGrowth in partner products supports Ligand’s asset-light royalty model, allowing revenue and margins to scale without carrying the cost of direct commercialization. Expanding partner sales can provide recurring economics over multiple years.
Expanded Royalty PortfolioThe XOMA acquisition materially broadens Ligand’s commercial and development portfolio, diversifies dependence on individual products, and extends potential royalty duration. More late-stage assets also create multiple paths to future milestone and royalty growth.
Strong Cash GenerationExpected operating cash flow gives Ligand internal funding for acquisitions, partnerships and corporate needs while reducing reliance on external capital. Strong cash conversion also supports the scalability of its partner-centric royalty model.
Bears Say
Higher Financial LeverageThe higher debt burden reduces balance-sheet flexibility and increases financial risk if royalty receipts or milestone income weaken. It may also constrain future acquisitions or raise financing dependence while Ligand integrates XOMA.
Uneven Cash-flow HistoryRecent cash generation is encouraging, but prior swings show that milestone timing, partner activity and portfolio events can make cash conversion inconsistent. This limits confidence that current cash-flow strength will persist evenly across periods.
Clinical And Regulatory Timing RiskAdditional clinical requirements delay potential approval, milestones and royalties from volixibat. More broadly, Ligand’s reliance on partner development means regulatory setbacks can defer or eliminate expected economics despite portfolio diversification.
Ligand Pharma News
LGDN FAQ
What was Ligand Pharma’s price range in the past 12 months?
Currently, no data Available
What is Ligand Pharma’s market cap?
Ligand Pharma’s market cap is CHF4.48B.
When is Ligand Pharma’s upcoming earnings report date?
Ligand Pharma’s upcoming earnings report date is Nov 05, 2026 which is in 71 days.
How were Ligand Pharma’s earnings last quarter?
Ligand Pharma released its earnings results on Aug 06, 2026. The company reported CHF1.922 earnings per share for the quarter, beating the consensus estimate of CHF1.63 by CHF0.292.
Is Ligand Pharma overvalued?
According to Wall Street analysts Ligand Pharma’s price is currently Undervalued.
Does Ligand Pharma pay dividends?
Ligand Pharma does not currently pay dividends.
What is Ligand Pharma’s EPS estimate?
Ligand Pharma’s EPS estimate is 1.87.
How many shares outstanding does Ligand Pharma have?
Ligand Pharma has 19,935,610 shares outstanding.
What happened to Ligand Pharma’s price movement after its last earnings report?
Ligand Pharma reported an EPS of CHF1.922 in its last earnings report, beating expectations of CHF1.63. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Ligand Pharma?
Currently, no hedge funds are holding shares in CH:LGDN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ligand Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF284.84 (― Upside)
CHF284.84 (― Upside)
Blogger Sentiment
Neutral
CH:LGDN Sentiment 57%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth CHF5.4M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
126.25%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
130.43%
Trailing 12-Months
Company Description
Ligand Pharma
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
LGDN Company Deck
LGDN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong operational and financial momentum: robust top-line and EPS growth, significant cash flow generation, completion of an accretive and scalable acquisition (XOMA), and successful low-cost financing that materially strengthens capital flexibility. Manageable near-term challenges include a product sales decline (Kyprolis), one-time charges, accounting complexity from increased financial royalty assets, and some timing risk from an FDA recommendation requiring a Phase III for PSC. On balance, the company presented multiple clear growth drivers and disciplined capital deployment that outweigh the identified risks.View all CH:LGDN earnings summariesLGDN Stock 12 Month Forecast
Average Price Target
――
Scholar Rock Holding
―
Crinetics Pharmaceuticals
―
Kymera Therapeutics
―
MoonLake Immunotherapeutics
―